Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Daphne L. van der Velden"'
Autor:
Kristel Kemper, Oscar Krijgsman, Xiangjun Kong, Paulien Cornelissen-Steijger, Aida Shahrabi, Fleur Weeber, Daphne L. van der Velden, Onno B. Bleijerveld, Thomas Kuilman, Roel J.C. Kluin, Chong Sun, Emile E. Voest, Young Seok Ju, Ton N.M. Schumacher, A.F. Maarten Altelaar, Ultan McDermott, David J. Adams, Christian U. Blank, John B. Haanen, Daniel S. Peeper
Publikováno v:
Cell Reports, Vol 16, Iss 1, Pp 263-277 (2016)
The therapeutic landscape of melanoma is improving rapidly. Targeted inhibitors show promising results, but drug resistance often limits durable clinical responses. There is a need for in vivo systems that allow for mechanistic drug resistance studie
Externí odkaz:
https://doaj.org/article/b4e20b0f1b48444f832fabb5c11f6dd8
Autor:
Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom, Paul Hamberg, Ann Hoeben, Derk Jan A. de Groot, Mariette Labots, Debbie G.J. Robbrecht, Niven Mehra, Anne M.L. Jansen, Wendy W.J. de Leng, Erik van Werkhoven, Paul Roepman, Laurien J. Zeverijn, Daphne L. van der Velden, J. Maxime van Berge Henegouwen, Louisa R. Hoes, Hanneke van der Wijngaart
Flow chart of patients with BRCA1/2 alterations submitted to the study team between September 2016 and December 2019, and reasons for drop-out, rejection or screen failure. Abbreviations: VUS = Variant of Unknown Significance, LOH = Loss of Heterozyg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65097be0eb5d177688ddeb4db508010b
https://doi.org/10.1158/1078-0432.22481003.v1
https://doi.org/10.1158/1078-0432.22481003.v1
Autor:
Emile E. Voest, Henk M.W. Verheul, Hans Gelderblom, Edwin Cuppen, Martijn P. Lolkema, Hans Morreau, Ann Hoeben, Mariette Labots, Carla M.L. van Herpen, Winette T.A. van der Graaf, Egbert F. Smit, Mathijs P. Hendriks, Laurens V. Beerepoot, Frans Erdkamp, Derk Jan de Groot, Emile D. Kerver, Jan Willem B. de Groot, Eelke H. Gort, Alwin D.R. Huitema, Vincent van der Noort, Erik van Werkhoven, Anne M.L. Jansen, Wendy J. de Leng, Paul Roepman, Joris van de Haar, Daphne L. van der Velden, Laurien J. Zeverijn, Hanneke van der Wijngaart, Jade M. van Berge Henegouwen, Louisa R. Hoes
Supplementary Figure from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::142be478802724901bf5b4aba218bf7c
https://doi.org/10.1158/1078-0432.22487285.v1
https://doi.org/10.1158/1078-0432.22487285.v1
Autor:
Emile E. Voest, Henk M.W. Verheul, Hans Gelderblom, Edwin Cuppen, Martijn P. Lolkema, Hans Morreau, Ann Hoeben, Mariette Labots, Carla M.L. van Herpen, Winette T.A. van der Graaf, Egbert F. Smit, Mathijs P. Hendriks, Laurens V. Beerepoot, Frans Erdkamp, Derk Jan de Groot, Emile D. Kerver, Jan Willem B. de Groot, Eelke H. Gort, Alwin D.R. Huitema, Vincent van der Noort, Erik van Werkhoven, Anne M.L. Jansen, Wendy J. de Leng, Paul Roepman, Joris van de Haar, Daphne L. van der Velden, Laurien J. Zeverijn, Hanneke van der Wijngaart, Jade M. van Berge Henegouwen, Louisa R. Hoes
Purpose:Patients with rare cancers (incidence less than 6 cases per 100,000 persons per year) commonly have less treatment opportunities and are understudied at the level of genomic targets. We hypothesized that patients with rare cancer benefit from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20708b4724c2bca311186b13b326a529
https://doi.org/10.1158/1078-0432.c.6532484
https://doi.org/10.1158/1078-0432.c.6532484
Autor:
Emile E. Voest, Henk M.W. Verheul, Hans Gelderblom, Edwin Cuppen, Martijn P. Lolkema, Hans Morreau, Ann Hoeben, Mariette Labots, Carla M.L. van Herpen, Winette T.A. van der Graaf, Egbert F. Smit, Mathijs P. Hendriks, Laurens V. Beerepoot, Frans Erdkamp, Derk Jan de Groot, Emile D. Kerver, Jan Willem B. de Groot, Eelke H. Gort, Alwin D.R. Huitema, Vincent van der Noort, Erik van Werkhoven, Anne M.L. Jansen, Wendy J. de Leng, Paul Roepman, Joris van de Haar, Daphne L. van der Velden, Laurien J. Zeverijn, Hanneke van der Wijngaart, Jade M. van Berge Henegouwen, Louisa R. Hoes
Supplementary Table from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::147164e4fc1bf7625772c998491fda4d
https://doi.org/10.1158/1078-0432.22487279
https://doi.org/10.1158/1078-0432.22487279
Autor:
Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom, Paul Hamberg, Ann Hoeben, Derk Jan A. de Groot, Mariette Labots, Debbie G.J. Robbrecht, Niven Mehra, Anne M.L. Jansen, Wendy W.J. de Leng, Erik van Werkhoven, Paul Roepman, Laurien J. Zeverijn, Daphne L. van der Velden, J. Maxime van Berge Henegouwen, Louisa R. Hoes, Hanneke van der Wijngaart
Supplementary Table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::682d1fd9a2218e77908d809143d1cd4a
https://doi.org/10.1158/1078-0432.22480997
https://doi.org/10.1158/1078-0432.22480997
Autor:
Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom, Paul Hamberg, Ann Hoeben, Derk Jan A. de Groot, Mariette Labots, Debbie G.J. Robbrecht, Niven Mehra, Anne M.L. Jansen, Wendy W.J. de Leng, Erik van Werkhoven, Paul Roepman, Laurien J. Zeverijn, Daphne L. van der Velden, J. Maxime van Berge Henegouwen, Louisa R. Hoes, Hanneke van der Wijngaart
Supplementary Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c673b41d7e1809c121882b30b75a551f
https://doi.org/10.1158/1078-0432.22481000
https://doi.org/10.1158/1078-0432.22481000
Autor:
Louisa R. Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J. Zeverijn, Daphne L. van der Velden, Joris van de Haar, Paul Roepman, Wendy J. de Leng, Anne M.L. Jansen, Erik van Werkhoven, Vincent van der Noort, Alwin D.R. Huitema, Eelke H. Gort, Jan Willem B. de Groot, Emile D. Kerver, Derk Jan de Groot, Frans Erdkamp, Laurens V. Beerepoot, Mathijs P. Hendriks, Egbert F. Smit, Winette T.A. van der Graaf, Carla M.L. van Herpen, Mariette Labots, Ann Hoeben, Hans Morreau, Martijn P. Lolkema, Edwin Cuppen, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest
Publikováno v:
Clinical Cancer Research, 28(7), 1402-1411. American Association for Cancer Research Inc.
Clinical Cancer Research, 28(7), 1402-1411. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research, 28, 1402-1411
Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, Zeverijn, L J, van der Velden, D L, van de Haar, J, Roepman, P, de Leng, W J, Jansen, A M L, van Werkhoven, E, van der Noort, V, Huitema, A D R, Gort, E H, de Groot, J W B, Kerver, E D, de Groot, D J, Erdkamp, F, Beerepoot, L V, Hendriks, M P, Smit, E F, van der Graaf, W T A, van Herpen, C M L, Labots, M, Hoeben, A, Morreau, H, Lolkema, M P, Cuppen, E, Gelderblom, H, Verheul, H M W & Voest, E E 2022, ' Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment ', Clinical Cancer Research, vol. 28, no. 7, pp. 1402-1411 . https://doi.org/10.1158/1078-0432.CCR-21-3752
Clinical cancer research, 28(7), 1402-1411. American Association for Cancer Research Inc.
Clinical Cancer Research, 28, 7, pp. 1402-1411
Clinical Cancer Research, 28(7), 1402-1411. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research, 28, 1402-1411
Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, Zeverijn, L J, van der Velden, D L, van de Haar, J, Roepman, P, de Leng, W J, Jansen, A M L, van Werkhoven, E, van der Noort, V, Huitema, A D R, Gort, E H, de Groot, J W B, Kerver, E D, de Groot, D J, Erdkamp, F, Beerepoot, L V, Hendriks, M P, Smit, E F, van der Graaf, W T A, van Herpen, C M L, Labots, M, Hoeben, A, Morreau, H, Lolkema, M P, Cuppen, E, Gelderblom, H, Verheul, H M W & Voest, E E 2022, ' Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment ', Clinical Cancer Research, vol. 28, no. 7, pp. 1402-1411 . https://doi.org/10.1158/1078-0432.CCR-21-3752
Clinical cancer research, 28(7), 1402-1411. American Association for Cancer Research Inc.
Clinical Cancer Research, 28, 7, pp. 1402-1411
Purpose: Patients with rare cancers (incidence less than 6 cases per 100,000 persons per year) commonly have less treatment opportunities and are understudied at the level of genomic targets. We hypothesized that patients with rare cancer benefit fro
Autor:
Derk Jan A. de Groot, Anne M.L. Jansen, Mariette Labots, Wendy W.J. de Leng, Hanneke van der Wijngaart, Ann Hoeben, L.J. Zeverijn, Hans Gelderblom, Henk M.W. Verheul, Debbie Robbrecht, L.R. Hoes, Emile E. Voest, Erik van Werkhoven, Daphne L. van der Velden, J. Maxime van Berge Henegouwen, Paul Roepman, Paul Hamberg, Niven Mehra
Publikováno v:
Clinical Cancer Research, 27(22), 6106-6114. American Association for Cancer Research Inc.
Clinical Cancer Research, 27, 6106-6114
Clinical Cancer Research, 27(22), 6106-6114. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research : an official journal of the American Association for Cancer Research, 27(22), 6106-6114. American Association for Cancer Research Inc.
Van Der Wijngaart, H, Hoes, L R, Van Berge Henegouwen, J M, Van Der Velden, D L, Zeverijn, L J, Roepman, P, Van Werkhoven, E, De Leng, W W J, Jansen, A M L, Mehra, N, Robbrecht, D G J, Labots, M, De Groot, D J A, Hoeben, A, Hamberg, P, Gelderblom, H, Voest, E E & Verheul, H M W 2021, ' Patients with Biallelic BRCA1/2 Inactivation respond to Olaparib treatment across Histologic tumor types ', Clinical Cancer Research, vol. 27, no. 22, pp. 6106-6114 . https://doi.org/10.1158/1078-0432.CCR-21-1104
Clinical cancer research, 27(22), 6106-6114. American Association for Cancer Research Inc.
Clinical Cancer Research, 27, 22, pp. 6106-6114
Clinical Cancer Research, 27, 6106-6114
Clinical Cancer Research, 27(22), 6106-6114. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research : an official journal of the American Association for Cancer Research, 27(22), 6106-6114. American Association for Cancer Research Inc.
Van Der Wijngaart, H, Hoes, L R, Van Berge Henegouwen, J M, Van Der Velden, D L, Zeverijn, L J, Roepman, P, Van Werkhoven, E, De Leng, W W J, Jansen, A M L, Mehra, N, Robbrecht, D G J, Labots, M, De Groot, D J A, Hoeben, A, Hamberg, P, Gelderblom, H, Voest, E E & Verheul, H M W 2021, ' Patients with Biallelic BRCA1/2 Inactivation respond to Olaparib treatment across Histologic tumor types ', Clinical Cancer Research, vol. 27, no. 22, pp. 6106-6114 . https://doi.org/10.1158/1078-0432.CCR-21-1104
Clinical cancer research, 27(22), 6106-6114. American Association for Cancer Research Inc.
Clinical Cancer Research, 27, 22, pp. 6106-6114
Purpose:To assess the efficacy of olaparib, a PARP inhibitor (PARPi) in patients with tumors with BRCA1/2 mutations, regardless of histologic tumor type.Patients and Methods:Patients with treatment-refractory BRCA1/2-mutated cancer were included for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55c98f524eeae4d08d3446ab9d9820a5
https://cris.maastrichtuniversity.nl/en/publications/6d297817-2a7a-4ceb-a790-898d766dde2f
https://cris.maastrichtuniversity.nl/en/publications/6d297817-2a7a-4ceb-a790-898d766dde2f
Autor:
Hans Gelderblom, Maxime van Berge Henegouwen, Emile E. Voest, Hanneke van der Wijngaart, L.R. Hoes, Henk M.W. Verheul, Daphne L. van der Velden
This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs* prescribed for treatment of patients with advanced cancer with a potentially actionable variant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f5020c79aacb4ff3ab41099d97da182
https://doi.org/10.21203/rs.3.pex-622/v1
https://doi.org/10.21203/rs.3.pex-622/v1